Apidel SA announces R&D collaboration with DNDi in the field of neglected diseases

Geneva, May 29 2017

Apidel announces the signature of an agreement to collaborate with DNDi on the preclinical development of a topical treatment for Cutaneous Leishmaniasis, a neglected disease affecting between 0.7 to 1.2 million people worldwide. A promising drug candidate will be tested with Apidel’s proprietary drug delivery technology ApidSOL™.
Apidel is a Geneva based early-stage pharmaceutical company providing proprietary drug delivery solutions for development of safer and more efficient therapeutic products. ApidSOL™ enables superior skin penetration of poorly soluble drugs.
Currently, there is no efficient topical treatment available for cutaneous leishmaniasis. A safe, affordable topical treatment, which could be stored in harsh conditions and self-administered represents an urgent, unmet need.
DNDi (Drugs for Neglected Diseases initiative) is a patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases – notably leishmaniasis, sleeping sickness, Chagas disease, filarial diseases, mycetoma, paediatric HIV, and hepatitis C – with several new drug candidates in its R&D pipeline.
Cutaneous leishmaniasis is a poverty-associated disease occurring mostly in subtropical regions or in displaced populations. It is a skin infection prompted by a parasite, resulting in multiple ulcers on exposed body parts causing serious disability and leaving deep scars which may induce serious social prejudice.

For further information :
DNDi https://www.dndi.org/
Apidel SA www.apidel.com
Vitalia Mitrovic, Apidel SA, Geneva vitalia.mitrovic@apidel.com